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Abstract
Rationale: Lung function measures are heritable traits that predict population morbidity and mortality and are essential for
the diagnosis of chronic obstructive pulmonary disease (COPD). Variations in many genes have been reported to affect
these traits, but attempts at replication have provided conflicting results. Recently, we undertook a meta-analysis of
Genome Wide Association Study (GWAS) results for lung function measures in 20,288 individuals from the general
population (the SpiroMeta consortium).
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Objectives: To comprehensively analyse previously reported genetic associations with lung function measures, and to
investigate whether single nucleotide polymorphisms (SNPs) in these genomic regions are associated with lung function in
a large population sample.
Methods: We analysed association for SNPs tagging 130 genes and 48 intergenic regions (+/210 kb), after conducting a
systematic review of the literature in the PubMed database for genetic association studies reporting lung function
associations.
Results: The analysis included 16,936 genotyped and imputed SNPs. No loci showed overall significant association for FEV1
or FEV1/FVC traits using a carefully defined significance threshold of 1.3610
25. The most significant loci associated with
FEV1 include SNPs tagging MACROD2 (P= 6.81610
25), CNTN5 (P= 4.3761024), and TRPV4 (P= 1.5861023). Among ever-
smokers, SERPINA1 showed the most significant association with FEV1 (P= 8.41610
25), followed by PDE4D (P= 1.2261024).
The strongest association with FEV1/FVC ratio was observed with ABCC1 (P= 4.38610
24), and ESR1 (P= 5.4261024) among
ever-smokers.
Conclusions: Polymorphisms spanning previously associated lung function genes did not show strong evidence for
association with lung function measures in the SpiroMeta consortium population. Common SERPINA1 polymorphisms may
affect FEV1 among smokers in the general population.
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Introduction
Pulmonary function is usually assessed by measurement of
forced expiratory volume in one second (FEV1), forced vital
capacity (FVC), and the ratio of FEV1 to FVC. The measurements
are integral to the diagnosis of chronic obstructive pulmonary
disease (COPD), and also are important long term predictors of
population morbidity and mortality [1]. Reduced FEV1/FVC
defines airways obstruction; whereas reduced FEV1 grades the
severity of obstruction [2].
Pulmonary function is determined by both environmental and
genetic factors. Tobacco smoking is the major environmental risk
factor for the development of COPD. A genetic contribution to
pulmonary function is well established with heritability estimates
reaching 77 percent for FEV1 [3]. Linkage analyses within families
have previously identified multiple genomic regions associated
with spirometry measures and respiratory diseases. In addition,
candidate gene studies have identified more than 100 genes which
have been suggested to contribute to variability in lung function.
The majority have been studied because of their potential
pathophysiological role in the development of COPD. Some
genes have been examined for association with lung function
measurements in individuals with other specific respiratory
diseases (most commonly asthma), or to a lesser extent, in the
general population. With the exception of SERPINA1, which is the
best documented genetic risk factor to influence the development
of COPD [4], these genes have not shown consistent associations
across different studies [5,6].
Recently, we established the SpiroMeta consortium and
published a large collective meta-analysis of lung function
genome-wide association studies (GWAS) in 20,288 individuals
of European origin, with follow-up of top SNPs in a further
54,276 individuals [7,8]. Our study confirmed the hedgehog
interacting protein (HHIP) association previously published
[9,10] and identified five new loci associated with FEV1 or
FEV1/FVC ratio including tensin 1 gene (TNS1), glutathione S-
transferase, C-terminal domain containing (GSTCD), 5-hydroxy-
tryptamine receptor 4 (HTR4), advanced glycosylation end
product-specific receptor (AGER), and thrombospondin, type I,
domain containing 4 (THSD4). A study with similar design by
the CHARGE consortium also identified HHIP, AGER, HTR4,
and GSTCD, and in addition suggested a potential role of five
additional genes (G protein-coupled receptor 126 (GPR126), a
disintegrin and metalloproteinase domain 19 (ADAM19), family
with sequence similarity 13, member A (FAM13A), patched
homolog 1 (PTCH1), and phosphotyrosine interaction domain
containing (PID1) [8].
The identification of these genes offers potential insight into
the pathophysiology of altered lung function. The SpiroMeta
consortium provides a powerful resource in which to study genetic
associations with lung function. We aimed to comprehensively
evaluate whether genes studied in candidate gene or small
genome-wide association studies, and reported to be associated
with lung function or COPD in these studies, were associated with
lung function measures in this large general population sample.
Results
Literature search
The literature search identified 1719 publications. Of these, 104
reported one or more genetic associations: these are listed in text
S1 in the online supporting information. These publications varied
according to their study designs and the populations studied. 47
papers reported association with COPD using case control or
family based designs. The remaining literature reported associa-
tion with lung function traits within populations with specific
respiratory diseases (asthma (26) and COPD (17)), or in general
population cohorts (14). Nine publications studied other popula-
tions which included patients with cystic fibrosis (2), SERPINA1
deficiency (2), cotton and grain workers (2), lung cancer (1), fire
fighters (1) and post myocardial infarction (MI) patients (1). Some
papers reported more than one endpoint.
These 104 relevant publications identified 130 genes and 48
intergenic SNPs. We investigated association between FEV1 and
FEV1/FVC and each of the 16,936 genotyped and imputed SNPs
spanning these regions in the SpiroMeta dataset.
Contribution of all tested genes to lung function
measures in SpiroMeta
Quantile-quantile (Q-Q) plots did not show large deviations
between observed and expected P values for FEV1 and FEV1/
FVC in all participants and for FEV1/FVC in ever-smokers
(Figure 1). The plot of FEV1 in ever-smokers, however, shows
slight deviations for high signal SNPs. The genomic inflation
factor, l for FEV1 is 0.83 in all individuals and 1.05 in smokers; l
for FEV1/FVC in all individuals is 0.92 and 1.13 in smokers.
Using the Bonferroni corrected P value threshold of 1.361025,
none of the tested SNPs demonstrated significant association with
either FEV1 or FEV1/FVC.
Association results in all individuals
In order to examine possible signals in greater detail, we also
explored region plots for the top SNPs identified (SNPs with the
lowest P values). The three top loci with the most significant P
values for all regions tested in all individuals are presented in
table 1.
Among all individuals, the strongest association with FEV1 was
with rs204652 in MACRO domain containing 2 (MACROD2) on
chromosome 20. SNP rs17133553 in Contactin 5 (CNTN5) on
chromosome 11 was the second top locus for association
with FEV1 and third for FEV1/FVC ratio. SNP rs803450 in
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like (MTHFD1L) on chromosome 6 showed association with FEV1
in all individuals. For FEV1/FVC ratio in all individuals the
strongest association was with rs3887893 in ATP-binding cassette,
sub-family C, member 1 (ABCC1) on chromosome 16, the second
strongest signal was for rs11155818 in estrogen receptor 1(ESR1)
on chromosome 6.
The region association plots around the most significant SNPs
associated with FEV1 and FEV1/FVC in all individuals provide
little evidence from supporting SNPs to suggest strong regions of
association in MACROD2, CNTN5, MTHFD1L, and ESR1, and
ABCC1 in these data (See figure S1 in the online supporting
information).
Association results in ever-smokers
To study the impact of smoking on potential genetic associations
with lung function, we repeated the analysis restricted to
individuals who had ever smoked (ever-smokers). The most
significant loci identified are shown in table 1.
Among ever-smokers, rs3748312 in serpin peptidase inhibitor,
clade A, member 1 (SERPINA1) on chromosome 14, also known as
alpha-1 antitrypsin (AAT) showed the strongest association with
FEV1. SNP rs298028 in Phosphodiesterase 4D, cAMP-specific
(phosphodiesterase E3 dunce homolog, Drosophila) (PDE4D) on
chromosome 5 showed the second strongest association with
FEV1, followed by MACROD2.
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The strongest association with FEV1/FVC ratio among
smokers was observed with rs9322335 in 1(ESR1) on chromo-
some 6. The second strongest association was rs1864271 in
with rhomboid domain containing 1 (RHBDD1) on chromo-
some 2, followed by rs1738567 in (MTHFD1L) on chromosome
6. The region association plots for SERPINA1 and PDE4D
among ever-smokers (figure 2) show some supportive evidence
for the association of these two loci. The region association
plots for the additional loci among ever-smokers reported in
table 1 are shown in figure S2 in the online supporting
information.
Association results excluding loci identified in previous
GWAS
Because some of the regions identified were observed in the
previously published small GWAS studies included in our
Figure 1. Quantile-quantile (Q-Q) plots of association results for FEV1 and FEV1/FVC. The Q-Q plot of association is shown for all
individuals in Panel A, and separately for ever-smokers only in panel B. Q-Q plots compare the observed P values (obs.p) to expected P values (exp.p)
on the logarithmic scale under the null hypothesis of no significant association. l: Lambda.
doi:10.1371/journal.pone.0019382.g001
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Table 1. Association results for the three most significantly associated loci.
Gene Locus SNP
SNP
function
coded
allele
Coded allele
frequency N eff Beta Se P
FEV1 All individuals
MACROD2 20p12.1 rs204652 Intron G 0.983 13551 20.187 0.047 6.8161025
CNTN5 11q21-q22.2 rs17133553 Intron T 0.966 13669 20.100 0.029 4.3761024
MTHFD1L 6q25.1 rs803450 Intron G 0.625 18497 0.036 0.011 1.0361023
FEV1 Smokers
SERPINA1 14q32.13 rs3748312 Intron T 0.167 9338 0.085 0.022 8.4161025
PDE4D 5q12 rs298028 Intron T 0.283 10829 20.069 0.018 1.2261024
MACROD2 20p12.1 rs204652 Intron G 0.983 6872 20.251 0.067 1.6761024
FEV1/FVC All individuals
ABCC1 16p13.1 rs3887893 Intron T 0.625 15509 20.043 0.012 4.3861024
ESR1 6q25.1 rs11155818 Intron G 0.992 12571 0.185 0.053 5.0261024
CNTN5 11q21-q22.2 rs1216170 Intron C 0.284 18863 0.039 0.011 6.0261024
FEV1/FVC Smokers
ESR1 6q25.1 rs9322335 Intron T 0.217 9495 20.061 0.018 5.4261024
RHBDD1 2q36.3 rs1864271 Intron G 0.708 7385 0.066 0.019 6.4061024
MTHFD1L 6q25.1 rs1738567 Intron C 0.367 10668 0.046 0.014 1.3361023
The table shows the three most significant loci associated with FEV1 and FEV1/FVC ratio in all individuals and ever-Smokers. N eff: the effective sample size. Beta:
regression coefficient on a transformed scale. Se: standard error. P: P value. Coded allele frequency based on HapMap Release 24. MACROD2: MACRO domain containing
2. CNTN5: Contactin 5.MTHFD1LMethylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like. SERPINA1: serpin peptidase inhibitor, clade A, member 1 (alpha-1
antitrypsin AAT). PDE4D: Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila). ABCC1: ATP-binding cassette, sub-family C, member
1. ESR1: estrogen receptor 1. RHBDD1: rhomboid domain containing 1.
doi:10.1371/journal.pone.0019382.t001
Figure 2. Regional association plots for SERPINA1 (A) and PDE4D among ever-smokers (B) in SpiroMeta. Statistical significance of each
SNP on the 2log10 scale as a function of chromosome position (NCBI build 36). The sentinel SNP at each locus is shown in blue; the correlations (r2)
of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. The relevant trait (FEV1 or FEV1/FVC ratio) is indicated for
each plot. Recombination rate is shown in pale blue.
doi:10.1371/journal.pone.0019382.g002
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literature search, we also present the top three genes for the
relevant end points after excluding GWAS hits (Table 2).
The additional genes identified in this analysis for association
with FEV1 among all individuals were the transient receptor
potential cation channel, subfamily V, member 4 (TRPV4) on
chromosome 12, and N-acetyltransferase 2 (NAT2) on chromo-
some 8. Among ever-smokers, association results for FEV1
identified B-cell CLL/lymphoma 2 (BCL2) on chromosome 18.
Association results for FEV1/FVC ratio identified allograft
inflammatory factor 1(AIF1) on chromosome 6 among all
individuals, and cluster of differentiation; CD22 molecule (CD22)
on chromosome 19 among ever-smokers. The region association
plots for the most significant loci in table 2 and not presented
earlier are shown in figure S3 in the online supporting
information. The plots show some additional support for all
presented loci except for ABCC1 among ever-smokers.
Discussion
In the SpiroMeta study, we generated a comprehensive
dataset to analyse associations between genetic variants and
lung function in the general population [7]. There have been
many small previous studies, mostly of individual candidate
genes examining association with lung function, which have
produced conflicting results. Therefore, in this paper, we
undertook a comprehensive literature review to identify relevant
gene regions and analysed potential associations with FEV1 and
FEV1/FVC ratio in all individuals within SpiroMeta. In
addition, given the impact of smoking on lung function, we also
analysed the associations separately in ever-smokers. There were
no strong association signals in never-smokers group (data
available on request).
The main conclusion from this study is that, within 178
previously reported regions, we found no SNP associations which
exceeded the significance threshold (P,1.361025) we employed
after correction for multiple testing. Our results suggest these
regions do not constitute major genetic determinants of lung
function measures at the general population level. The lack of
replication and sometimes contradicting results in previous studies
may reflect the fact that many previously reported associations
came from studies with small sample sizes, possibly leading to false
positive results.
Despite the failure to identify any overall significant contribu-
tion of a single SNP from previously reported genes to lung
function, there are some potentially interesting signals apparent
from the region plots suggesting that there may be a small signal
from variants in some of the genes of interest.
SERPINA1 showed the strongest association with FEV1 among
smokers (8.4161025). It encodes alpha-1 Antitrypsin protein
(AAT), mainly produced in the liver and has the primary role of
inhibiting neutrophil elastase in the lungs [11]. Protein variants of
this gene have been classified based on their migration in an
isoelectric pH gradient from A to Z. Among Caucasians, the M
allele is the most common allele with six subtypes: M1–M6 with
allele frequencies greater than 95 percent and associated with
normal AAT levels. The common deficiency variants; S (frequency
0.02–0.03) and Z (frequency 0.01–0.03), are associated with mild
and severe reductions in serum AAT levels, respectively [11,12].
The r2 between the Z allele rs28929474 and rs3748312 is 0.08
(based on 1000 Genomes Project pilot 1 data from 120 CEU
individuals). Our top SNP, rs3748312, is in LD (r2 = 0.603) with
the M1 allele SNP rs6647, but is in very weak LD with M2
rs709932 (r2 = 0.033) and M3 rs1303 (r2 = 0.051). The S allele SNP
rs45551939 (merged into rs17580) was not found in HapMap
Table 2. Association results for the most significant loci excluding genes identified in GWAS.
gene locus SNP SNP function
coded
allele
Coded allele
Frequency N eff Beta se P
FEV1 All
PDE4D 5q12 rs172362 Intron C 0.133 18929 20.048 0.015 1.3661023
TRPV4 12q24.1 rs3742030 Missense G 0.992 17591 20.110 0.035 1.5861023
NAT2 8p22 rs6988857 Intergenic T 0.241 20080 0.035 0.011 2.3761023
FEV1 Smokers
SERPINA1 14q32.13 rs3748312 Intron T 0.167 9338 0.085 0.022 8.4161025
PDE4D 5q12 rs298028 Intron T 0.283 20829 20.069 0.018 1.2261024
BCL2 18q21.3 rs2850760 Intron T 0.425 10888 0.050 0.014 4.6661024
FEV1/FVC All
ABCC1 16p13.1 rs3887893 Intron T 0.625 15509 20.043 0.012 4.3861024
ESR1 6q25.1 rs11155818 Intron G 0.992 12571 0.185 0.053 5.0261024
AIF1 6p21.3 rs3132451 59near gene G 0.883 19889 0.045 0.014 7.8461024
FEV1/FVC Smokers
ESR1 6q25.1 rs9322335 Intron T 0.217 9495 20.061 0.018 5.4261024
ABCC1 16p13.1 rs3887893 Intron T 0.625 8156 20.054 0.017 1.3661023
CD22 19q13.1 rs7251526 Intron T 0.246 8328 20.054 0.018 2.0061023
The table shows association results for the three most significant loci associated with FEV1 and FEV1/FVC, in all individuals and in ever-smokers after excluding genes
identified in GWAS. N eff: the effective sample size. Beta: regression coefficient on a transformed scale. Se: standard error. P: P value. Coded allele frequency based on
HapMap Release 24. PDE4D: Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila). TRPV4: transient receptor potential cation
channel, subfamily V, member 4. NAT2: N-acetyltransferase 2. SERPINA1: serpin peptidase inhibitor, clade A, member 1 (alpha-1 antitrypsin AAT). BCL2: B-cell CLL/
lymphoma 2. ABCC1: ATP-binding cassette, sub-family C, member 1. AIF1: allograft inflammatory factor 1. ESR1: estrogen receptor 1. CD22: cluster of differentiation;
CD22 molecule.
doi:10.1371/journal.pone.0019382.t002
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(version24). It is possible that the signal observed in our data is due
to variants with effects on gene expression and/or protein levels,
and this idea is supported by a previous study showing novel
variants in SERPINA1 to be associated with increased susceptibility
to COPD independently of the Z allele [13]. The relatively strong
signal observed in our study suggests a possible role for variants in
SERPINA1 in smokers at the general population level beyond that
observed in carriers of known deficient alleles.
The PDE4D gene encodes the type 4D phosphodiesterase,
which degrades cyclic adenosine monophosphate (cAMP), an
important signal transduction molecule in all cell types. Polymor-
phisms within PDE4D have been associated with stroke [14], and
bone mineral density [15]. PDE4D is the most dominant
phosphodiesterase in the lungs and plays an important role in
regulating airway smooth muscle contractility [16] demonstrated
by PDE4D knockout mice lacking response to methacholine [17].
A study in a Japanese population reported association of one
PDE4D SNP (rs829259) and a haplotype consisting of rs10075508
and one interleukin 13 (IL13) SNP with COPD [18]. SNP
rs829259 was not associated with FEV1 in all individuals (P = 0.68)
and in smokers (P = 0.21) in our study, and SNP rs10075508 was
not genotyped or imputed in SpiroMeta. A recent GWAS has also
identified PDE4D as an asthma susceptibility gene [19], however,
none of the top 5 SNPs associated with asthma is present in our
dataset, and the linkage disequilibrium (LD) with SNPs in
SpiroMeta is low, so it is difficult to comment on their contribution
to lung function measures in our study.
Our study has a number of strengths. First, we have power to
detect associations of small magnitude, with data on 20,288
individuals from 14 European studies with more than 2.5 million
genotyped and imputed SNPs. Second, we aimed to minimise
Type 1 error whilst taking appropriate account of the correlation
between neighbouring SNPs. Finally, the literature search was
designed to be comprehensive to include all reported genetic
variants with effect on lung function irrespective of disease status
or ethnicity. To our knowledge, this is the first study to
comprehensively evaluate the role of previously associated genes
in a large genome-wide association study.
However, it is important to recognise the limitations of our
study. We have tested for association in a general population
sample; the magnitude of effect of these genetic variants may be
greater in populations enriched with individuals with respiratory
diseases such as asthma and COPD. Second, we have tested with
cross sectional lung function measures. Some of the variants tested
might affect longitudinal changes by accelerating or decelerating
the decline in lung function, although this would still be expected
to result in effects evident in cross sectional data. Third, the power
of our study to detect associations of SNPs with modest effect sizes
on lung function was limited given our relatively conservative
approach to multiple testing, therefore we cannot rule out a real
but modest effect of some of these loci on lung function and
susceptibility to respiratory diseases in the general population.
Alternative approaches could be to utilise a priori evidence about
the reported direction of effect and a priori assumptions about the
likely presence of multiple causal variants. Fourth, we tested for
association with lung function measures among individuals of
European ancestry, and the contribution of these variants to lung
function in other populations may vary. Finally, the coverage of
tested genetic regions varies depending on the genome-wide arrays
used and imputation quality metrics.
In conclusion, we have shown that none of the SNPs tagging the
genes previously reported to determine lung function were
significantly associated with FEV1 or FEV1/FVC ratio in the
SpiroMeta general population study. We found some evidence to
suggest a possible contribution for the SERPINA1 and PDE4D loci
to lung function in smokers which warrant further study. As a
resource to the scientific community we have provided the
complete association results (Dataset S1) in the online supporting
information.
Methods
Systematic Literature search
We conducted a literature search in PubMed in October 2009
for genetic association studies of lung function measurements and/
or COPD. The search terms used were: ‘‘Lung function’’ OR
‘‘pulmonary function’’ OR ‘‘FEV1’’ OR ‘‘FEV1/FVC’’ OR
‘‘Forced Expiratory Volume’’ OR ‘‘Forced Vital Capacity’’ OR
‘‘ASTHMA’’ OR ‘‘COPD’’ OR ‘‘BRONCHIAL HYPERRE-
SPONSIVENESS’’ OR ‘‘BHR’’ OR ‘‘obstructive lung disease’’
AND ‘‘SNP’’ OR ‘‘single nucleotide polymorphism’’ OR
‘‘polymorphism’’ OR ‘‘gene’’ OR ‘‘genetic’’ OR ‘‘genom*’’ OR
‘‘variation’’ AND ‘‘Linkage’’ OR ‘‘association’’
From the search results, we included relevant papers reporting
only positive association results. For the three GWAS papers
identified, we took a more inclusive approach and included all loci
presented in the publication body, and not just those meeting
genome-wide significance. We excluded papers reporting associ-
ations with respiratory diseases (e.g. asthma) without association
with lung function measurements.
Statistical analysis
The genes and intergenic SNPs identified in the relevant
literature were evaluated in the SpiroMeta dataset using an
extended region of +/210 kilobases (kb) from the gene coordi-
nates downloaded from the UCSC genome browser (we used the
SNP coordinate +/210 kb for intergenic SNPs). Meta-analysis
association results for SNPs in these (+/210 kb extended) regions
were extracted from the SpiroMeta dataset for both FEV1 and
FEV1/FVC in all individuals and separately in ever–smokers. The
complete cohort descriptions, study design and methods have been
previously reported [7], but we provide here a brief summary. At
study level, non-genotyped SNPs were imputed using standard
approaches [18,20] to facilitate meta-analysis of studies employing
different genotyping platforms. Thus up to 2,705,257 SNPs were
tested for association with FEV1 and FEV1/FVC using additive
models and adjusting for age, sex, height and ancestry principal
components. Then, the results were meta-analysed across studies
using inverse variance weighting. Genomic control was applied at
the study level and after the meta-analysis to correct for test
inflation due to population stratification [21]. We excluded SNPs
which were not well measured or imputed in the study (identifiable
by an ‘‘effective sample size’’ of,50% of the total sample size) [7].
In all, we identified 16,936 genotyped and imputed SNPs in the
gene and intergenic regions described above which met our
inclusion criteria.
In order to correct for multiple testing of SNPs in linkage
disequilibrium we used Li and Ji’s [22] method for calculating the
effective number of independent tests from pairwise SNP
correlations. Pairwise SNP correlations were obtained from
reference genotypes of 1468 subjects in the Busselton study [23].
We estimated that the association tests for the 16,936 highly
correlated SNPs we selected in the regions of interest equated to
3,891 independent tests.
To maintain a Type 1 error rate of 5%, we adjusted the
significance threshold using a Bonferroni correction (0.05/3891).
Thus a threshold of 1.361025 was used to determine statistical
significance.
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Supporting Information
Figure S1 Regional association plots of the most significant lung
function–associated loci among all individuals in SpiroMeta (A–F).
Statistical significance of each SNP on the 2log10 scale as a
function of chromosome position (NCBI build 36). The sentinel
SNP at each locus is shown in blue; the correlations (r2) of each of
the surrounding SNPs to the sentinel SNP are shown in the
indicated colours. The relevant trait (FEV1 or FEV1/FVC ratio) is
indicated for each plot. Recombination rate is shown in pale blue.
(TIFF)
Figure S2 Regional association plots of the most significant lung
function–associated loci among ever-smokers in SpiroMeta (A–D).
Statistical significance of each SNP on the 2log10 scale as a
function of chromosome position (NCBI build 36). The sentinel
SNP at each locus is shown in blue; the correlations (r2) of each of
the surrounding SNPs to the sentinel SNP are shown in the
indicated colours. The relevant trait (FEV1 or FEV1/FVC ratio) is
indicated for each plot. Recombination rate is shown in pale blue.
(TIF)
Figure S3 Regional association plots of the most significant lung
function–associated loci (A–G) after excluding genes identified in
GWAS. Statistical significance of each SNP on the2log10 scale as
a function of chromosome position (NCBI build 36). The sentinel
SNP at each locus is shown in blue; the correlations (r2) of each of
the surrounding SNPs to the sentinel SNP are shown in the
indicated colours. The relevant trait (FEV1 or FEV1/FVC ratio)
and whether it is in all individuals or ever-smokers is indicated for
each plot. Recombination rate is shown in pale blue.
(TIF)
Text S1 The 104 relevant publications identified in the literature
search.
(DOC)
Dataset S1 Complete FEV1 and FEV1/FVC association results
for all individuals and separately for ever-smokers.
(XLS)
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